Pharmacoeconomic benefits of capecitabine-based chemotherapy in metastatic colorectal cancer.
Chu
Edward
E
Cartwright
Thomas H
TH
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000191:economics; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000191:economics* / Q000627:therapeutic use*; D000069287:Capecitabine; D015179:Colorectal Neoplasms / Q000191:economics* / Q000473:pathology / Q000628:therapy*; D003362:Cost-Benefit Analysis; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D016527:Drug Costs; D017850:Economics, Pharmaceutical; D005472:Fluorouracil / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000191:economics; D017721:Hospital Costs; D006801:Humans; D018803:Models, Economic; D009362:Neoplasm Metastasis; D018579:Patient Selection; D012107:Research Design; D016896:Treatment Outcome
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil